GTC Biotherapeutics (fka GTCB)

[DewDiligence]

The rationale for the deal is that Ovation has an established hospital salesforce for acute-care drugs in general and hematology in particular. These are the marketed products listed on the company’s website:

http://www.ovationpharma.com/products.php

HOSPITAL
Chemet®
Cogentin®
Indocin® I.V.
Intravenous Sodium Diuril®
NeoProfen®

HEMATOLOGY/ONCOLOGY
Cosmegen® for Injection
Elspar®
Mustargen®
Panhematin®

Although the fit between the companies looks good, the scant $5M in deal payments that GTC expects in 2008 is disappointing, IMO.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”